Published online 19 May 2008
Haematologica, Vol 93, Issue 7, 1039-1048 doi:10.3324/haematol.12402
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Romano, S.
Right arrow Articles by Romano, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Romano, S.
Right arrow Articles by Romano, M. F.

Lymphoproliferative Disorders

The effect of FK506 on transforming growth factor β signaling and apoptosis in chronic lymphocytic leukemia B cells

Simona Romano1, Maria Mallardo1, Federico Chiurazzi1, Rita Bisogni1, Anna D’Angelillo1, Raffaele Liuzzi2, Giovanna Compare1, Maria Fiammetta Romano1

1 Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples
2 Institute of Biostructure and Bio-Imaging-National Research Council (CNR), Naples, Italy

Correspondence: Maria Fiammetta Romano, MD, Department of Biochemistry and Medical Biotechnologies, Federico II University, via Pansini, 5. 80131. Naples, Italy. E-mail:romano{at}dbbm.unina.it

Background: Loss of response to transforming growth factor-beta (TGF-β ) is thought to contribute to the progression of chronic lymphocytic leukemia. Recent findings of over-activation of the TGF-β signal in FKBP12-knockout mouse prompted us to investigate whether FK506, the canonical ligand of FKBP, can activate the TGF-β signal in chronic lymphocytic leukemia.

Design and Methods: We studied 62 chronic lymphocytic leukemia samples from patients with Rai/Binet stage 0 to 4 disease. The TGF-β signal was investigated by western blotting and flow cytometry. The levels of Bcl2-family members and death-associated-protein kinase were also investigated by western blotting, whereas apoptosis was studied in flow cytometry. Down-modulation of FKBP12 was obtained by gene silencing with short interfering RNA.

Results: Twenty-two out of 62 chronic lymphocytic leukemia samples were sensitive to TGF-β-induced apoptosis. All but two of the responsive samples underwent apoptosis also when cultured with FK506, but not with cyclosporine. Thirteen samples that were not sensitive to TGF-β were sensitive to FK506. Overall, response to FK506 occurred in 33 samples. FK506 induced Smad2 phosphorylation and nuclear translocation. Accordingly, death-associated-protein kinase, a transcriptional target of Smad, was induced. At the same time, Bcl-2 and Bcl-xL levels decreased whereas the levels of Bim and Bmf increased. A loss of mitochondrial membrane potential preceded caspase activation and cell death. FK506 removed FKBP12 from its binding to the TGF-β-receptor. FKBP12 release activated the receptor-kinase activity as suggested by the enhanced levels of phospho-Smad found in cells depleted of FKBP12.

Conclusions: Our study shows that most chronic lymphocytic leukemia cells escape the homeostatic control of TGF-β and that FK506 restores the TGF-β signal in a proportion of non-responsive samples. We demonstrated that FK506 activates TGF-β receptor I kinase activity in chronic lymphocytic leukemia, which transduces apoptosis by a mitochondrial-dependent pathway.

Key words: FK506, chronic lymphocytic leukemia, TGF-β, apoptosis.